<DOC>
	<DOCNO>NCT02666846</DOCNO>
	<brief_summary>This randomise , double blind , cross clinical study healthy human volunteer ( include pharmacokinetic [ PK ] sample laser Doppler assessment local blood flow subset 6 subject per cohort 20 ) ass efficacy safety three different topical analgesic ( DCF100 , TIB200 SPR300 ) versus placebo active control ( ) model UV-induced inflammatory pain .</brief_summary>
	<brief_title>Assess Efficacy Safety Volunteers DCF100 , TIB200 SPR300 v . Placebo Control ( ) UV Pain Model</brief_title>
	<detailed_description>This randomise , double blind , cross clinical study healthy human volunteer , include pharmacokinetic ( PK ) sample laser Doppler assessment local blood flow subset 6 subject per cohort , assess efficacy safety three different topical analgesic ( DCF100 , TIB200 SPR300 ) versus placebo active control ( ) model UV-induced inflammatory pain . The study consist 3 cohort subject ( n=20 subject per cohort ) . Subjects cohort receive test reference product ( reference product Cohort 3 ) one investigational medicinal product ( IMP ) placebo . Test Products : Cohort 1 : Ibuprofen , TIB200 gel ( 10 % , w/w ) Cohort 2 : Diclofenac , DCF100 gel ( 2 % 4 % , w/w ) Cohort 3 : Methyl-salicylate Menthol , SPR300 gel ( 15 % :7 % , w/w ; ratio Methylsalicylate Menthol ) Reference Products : Cohort 1 : Ibuprofen , Nurofen Max Strength gel ( 10 % , w/w ) , Ibuprofen , Nurofen , oral tablet ( 400 mg ) Cohort 2 : Voltaren Emulgel ( 2 % ) , Voltarol oral tablet ( 50 mg ) Placebo : All Cohorts : Test product match vehicle gel . Pharmacodynamic test PK blood draw perform : pre-dose , 1 , 2 , 4 , 6 hour post dose treatment cohort treatment day ( PK blood sample 6 subject per cohort ) . Safety evaluate incidence local systemic treatment-emergent adverse event ( TEAEs ) report treatment . Safety assessment also include vital sign , 12-Lead Electrocardiograms ( ECGs ) , laboratory test physical examination Screening Follow-up visit .</detailed_description>
	<mesh_term>Menthol</mesh_term>
	<mesh_term>Diclofenac</mesh_term>
	<mesh_term>Ibuprofen</mesh_term>
	<mesh_term>Salicylates</mesh_term>
	<mesh_term>Methyl salicylate</mesh_term>
	<criteria>1 . Were able provide write informed consent . 2 . Male 18 65 year old , inclusive , time screen . 3 . Good general health ascertain detailed medical history physical examination . 4 . Body mass index ( BMI ) ≥18 ≤29 kg/m2 ( BMI = weight/height2 ) , time screen . 5 . No clinically relevant abnormality 12lead ECG per PI 's judgement , e.g. , absence cardiac rhythm disorder , particular bradycardia ( &lt; 40 beat per minute ) , conduction abnormality atrioventricular block , absence active ischemia ( unstable angina pectoris ) recent myocardial infarction , QTcF interval &gt; 450 millisecond , QRS complex ≥120 millisecond , Screening . 6 . No clinically relevant abnormality result laboratory test per PI 's judgement ; particular , significant liver impairment define aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) 1.5x upper limit normal ( ULN ) ; significant kidney impairment define serum creatinine 2x ULN ; abnormal thyroid function define thyroidstimulating hormone ( TSH ) total thyroxin ( T4 ) ( TSH within range 0.27 4.2 mIU/L , total T4 within range 59 154 nmol/L ) . 7 . Had skin type II III ( Fitz Patrick classification ) . 8 . Nonsmokers exsmokers least 6 month prior Screening Visit , confirm urine cotinine test . 9 . Subjects able communicate well PI/designee . 1 . History hypersensitivity IMP excipients medicinal product similar chemical structure . 2 . Presence clinically relevant acute chronic disease could interfere subject safety study , expose subject undue risk , limit biological sampling ( e.g. , blood collection ) , interfere absorption IMP ( e.g. , active dermatological condition application site , ulcer , irritable bowel syndrome ) interfere study objective . 3 . Skin type I , IV , V VI ( Fitzpatrick Classification ) . 4 . History chronic pain symptom ( &gt; 6 month ) ongoing pain . 5 . Any condition require regular concomitant medication include herbal product , predict need concomitant medication Screening Visit end study . 6 . Intake medication include counter ( OTC ) medication ( particular pain killer ) , herbal dietary supplement St John 's Wort , vitamins mineral could affect outcome study , within 48 hour first administration investigational product duration study . 7 . Use photosensitising medication , phenothiazine , tetracycline , quinolones , sulphonamides , nalidixic acid , nonsteroidal antiinflammatories , furosemide , hydrochlorothiazide , fibrate , phytotherapeutic drug ( herbal supplement ) , phenothiazine , quinidine , psoralens amiodarone within 4 week first UVB irradiation duration study . 8 . Any skin disease , acute chronic ( e.g. , psoriasis vulgaris , neurodermatitis ) auto immune disease associate increase light sensitisation . 9 . Any active dermatological condition , local pigmentary disorder , body art ( e.g. , tattoo ) , excessive hair growth lower back might interfere study assessment absorption IMP . 10 . History skin cancer ( i.e. , melanoma , squamous cell carcinoma basal cell carcinoma ) . 11 . History condition increase risk melanoma ( e.g. , dysplastic nevus [ &gt; 5 nevus ] , xeroderma pigmentosum , Fanconi anaemia , Bloom 's syndrome , Werner syndrome , Cockayne syndrome , trichothiodystrophy , familial mole melanoma syndrome ) . 12 . History bleed disorder , peptic ulceration gastro intestinal bleeding , heart burn , cardiovascular disease , myocardial infarction stroke . 13 . Inability give reproducible HPPT rating naïve skin screening , ( define HPTT test retest difference ≥1.0 °C ) 14 . Heat pain perception threshold &lt; 40°C &gt; 51°C naïve skin Screening . 15 . Supine systolic blood pressure ( SBP ) &lt; 90 mmHg &gt; 140 mmHg , supine diastolic blood pressure ( DBP ) &lt; 50 mmHg &gt; 90 mmHg 5 minute supine , Screening Visit . 16 . Positive test result HBsAg , HCVAb HIV1 and/or 2 antibody Screening . 17 . Excessive use caffeinecontaining beverage exceed 500 mg caffeine/day ( 5 cup coffee ) inability refrain use caffeinecontaining beverage confinement Clinical Unit . 18 . Excessive alcohol consumption ( regular alcohol intake ≥21 unit per week ) . Use alcohol 48 hour study visit , confirm urine alcohol test Screening , Day 2 , additional test discretion PI . 19 . History last year presence drug addiction ( positive urine drug screen ) Screening Day 2 . 20 . Presence history alcohol abuse last year , confirm subject 's general practitioner ( GP ) . 21 . Blood donation within 8 week first IMP administration . 22 . Participation another study experimental drug within 3 month first dose day . 23 . Any psychological , emotional problem , disorder resultant therapy likely invalidate inform consent , limited ability subject comply protocol requirement . 24 . Unlikely comply protocol requirement , instruction studyrelated restriction ; e.g. , uncooperative attitude , inability return Followup visit improbability complete clinical study . 25 . Planned surgery , dental procedure , hospitalisation Screening Visit end study . 26 . Inability give write informed consent comply fully protocol . 27 . Subjects , opinion PI , consider unsuitable reason .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>UVB Pain Model</keyword>
	<keyword>PK</keyword>
	<keyword>Topical</keyword>
	<keyword>NSAIDs</keyword>
</DOC>